Gene Name	Entrez ID	Drug Name	Chembl ID	Interaction Types	Sources	publications
CRP	1401	PHOSPHOCHOLINE	CHEMBL1235161		DrugBank	17139284, 17016423
CRP	1401	CHEMBL406845	CHEMBL406845	antisense	TTD

Gene Name	Variant	Alleles	Chemical	Phenotype Category	Significance	Notes	Sentence	Publications	Annotation ID
CRP	rs3093059	AA	fenofibrate	efficacy	no	No significant difference in the change of C-reactive protein (CRP) levels between baseline and 3 weeks of treatment, was seen between genotypes. In strong linkage disequilibrium with rs3091244 (r2 = 0.935, p < 0.001) and in weak linkage disequilibrium with rs1417938 and rs1205 (r2 = 0.17, p < 0.05).	Genotype AA is not associated with response to fenofibrate in people with Metabolic Syndrome as compared to genotypes AG + GG.	18285551	982044478
CRP	rs1417938	TT	fenofibrate	efficacy	yes	Patients with the TT genotype had a greater reduction in C-reactive protein (CRP) levels between baseline and 3 weeks of treatment, as compared to carriers of the A allele. In strong linkage disequilibrium with rs3091244 and rs1205 (r2 = 0.4 - 0.9, p < 0.001) and in weak linkage disequilibrium with rs3093059 (r2 = 0.17, p < 0.05).	Genotype TT is associated with increased response to fenofibrate in people with Metabolic Syndrome as compared to genotypes AA + AT.	18285551	982044398
CRP	rs3091244	AG + GG	fenofibrate	efficacy	yes	Patients with the GG, GA and GT genotypes had a greater reduction in C-reactive protein (CRP) levels between baseline and 3 weeks of treatment, as compared to those with the AA and AT genotypes. In strong linkage disequilibrium with rs1205 and rs1417938 (r2 = 0.4 - 0.9, p < 0.001) and rs3093059 (r2 = 0.935, p < 0.001).	Genotypes AG + GG are associated with increased response to fenofibrate in people with Metabolic Syndrome as compared to genotypes AA + AT.	18285551	982044407
CRP	rs3091244	GG + GT	fenofibrate	efficacy	yes	Patients with the GG, GA and GT genotypes had a greater reduction in C-reactive protein (CRP) levels between baseline and 3 weeks of treatment, as compared to those with the AA and AT genotypes. In strong linkage disequilibrium with rs1205 and rs1417938 (r2 = 0.4 - 0.9, p < 0.001) and rs3093059 (r2 = 0.935, p < 0.001).	Genotypes GG + GT are associated with increased response to fenofibrate in people with Metabolic Syndrome as compared to genotypes AA + AT.	18285551	982044416
CRP	rs1130864	AG + GG	adalimumab	efficacy	yes	Alleles given as C and T. Treatment protocol was 160 mg of adalimumab at week zero, 80 mg at week 2, and a maintenance dose of 40 mg every other week. Response measured with the Inflammatory Bowel Disease Questionnaire (IBDQ) score, with IBDQ score higher than 170 or an increase of at least 22 points.	Genotypes AG + GG are associated with increased response to adalimumab in people with Inflammatory Bowel Diseases as compared to genotype AA.	27096233	1447988304
CRP	rs1205	CC	fenofibrate	efficacy	no	No significant difference in the change of C-reactive protein (CRP) levels between baseline and 3 weeks of treatment, was seen between genotypes. In strong linkage disequilibrium with rs3091244 and rs1417938 (r2 = 0.4 - 0.9, p < 0.001) and in weak linkage disequilibrium with rs3093059 (r2 = 0.17, p < 0.05).	Genotype CC is not associated with response to fenofibrate in people with Metabolic Syndrome as compared to genotypes CT + TT.	18285551	982044434